Moderna and Merck's mRNA Melanoma Vaccine Looks Like a Game Changer
Moderna and Merck have announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, intismeran autogene. The vaccine, designed to prevent melanoma recurrence, showed significant efficacy when combined with immunotherapy.
Why it matters
This represents a major breakthrough in personalized medicine, potentially transforming how high-risk cancers are treated and prevented.
The future of cancer treatment is looking brighter thanks to trial results jointly announced this week by the pharmaceutical companies Moderna and Merck.
On Wednesday, the companies disclosed the primary findings of a Phase 3 trial that tested their mRNA-based vaccine, which is designed to prevent people’s melanoma from returning. People who received the vaccine in combination with immunotherapy lived significantly longer without cancer reoccurrence than those who only received immunotherapy, the trial reportedly showed. If approved, this vaccine could herald an important new approach to keeping cancers at bay.
“These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient’s cancer was aspirational. We are now helping turn that vision into a reality,” said Stéphane Bancel, CEO of Moderna, in a statement released by the companies.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in